Clicky

Adicet Bio Inc(1IJA)

Description: Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.


Keywords: Biotechnology Cancer Solid Tumors Autoimmune Disease Cell Therapy Gene Therapy Lymphoma Hematological Malignancies Renal Cell Carcinoma Treatment Of Autoimmune Disease Hodgkin Tumors Of The Hematopoietic And Lymphoid Tissues Clusters Of Differentiation Cd20 Car T Cell Therapies For Autoimmune Diseases

Home Page: www.adicetbio.com

131 Dartmouth Street
Boston, MA 02116
United States
Phone: 650 503 9095


Officers

Name Title
Mr. Chen Schor BA, CPA, M.B.A. CEO, President & Director
Dr. Aya Jakobovits Ph.D. Founder & Independent Director
Mr. Brian Nicholas Harvey Chief Financial Officer
Dr. Donald Healey Ph.D. Chief Technology Officer
Dr. Blake Aftab Ph.D. Senior VP & Chief Scientific Officer
Ms. Amy Locke Chief Human Resource Officer
Dr. Francesco Galimi M.D., Ph.D. Chief Medical Officer & Senior VP
Dr. Nancy L. Boman M.D., Ph.D. Senior VP & Chief Regulatory Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.3581
Price-to-Sales TTM: 9.6888
IPO Date:
Fiscal Year End: December
Full Time Employees: 143
Back to stocks